Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hovione Names Particle Design Unit VP | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Hovione Names Particle Design Unit VP

Minchom brings 29 years of drug development experience

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dr. Colin Minchom has been appointed vice president of Hovione’s Particle Design Business Unit. Dr. Minchom joins the company from Patheon, where he served as vice president of Pharmaceutical Development Services for North America. Based in East Windsor, NJ, Dr. Minchom will report to Guy Villax, Hovione’s chief executive officer.
 
“We are very pleased to welcome Dr. Minchom to Hovione. He is an excellent addition to our management team in an area of critical importance to our customers. Dr. Minchom is responsible for innovating Hovione’s Pharmaceutical Particle Design offerings to meet the development and commercial supply needs of the formulator with poorly bioavailable or otherwise challenging molecules,” said Mr. Villax.
 
Dr. Minchom has 29 years of experience in the process, science and global regulation of drug development with emphasis on dosage forms and drug delivery. Prior to this role at Patheon Dr. Minchom was head of Pharmaceutical Sciences at Cerebrus Ltd., a UK pharmaceutical company. He also held positions of increasing responsibility at Eli Lilly and E.R. Squibb in formulation and product development, project management and product management.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics